Aeterna Zentaris Inc. has received orphan drug designation from the FDA for AEZS-108, a doxorubicin targeted conjugate compound for the treatment of ovarian cancer. AEZS-108 is currently in a Phase II trial in advanced ovarian and endometrial cancer. Orphan drug designation is granted to new drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides a seven-year period of marketing exclusivity if approved, or if it demo...